Form 4: Cabaletta Bio Director Simon Mark Reports Stock Option Grant

Director Simon Mark reports the acquisition of stock options in Cabaletta Bio, Inc.

Summary

• On June 3, 2024, Simon Mark, a director of Cabaletta Bio, Inc., reported the acquisition of stock options.
• The stock option grants the right to buy 22,000 shares of common stock at an exercise price of $10.01.
• The options vest fully on the earlier of June 3, 2025, or the date of the next annual meeting of the Corporation's stockholders.
• The options expire on June 2, 2034.
• Following the transaction, Simon Mark directly owns 22,000 derivative securities.

Sentiment

Score: 5

Explanation: The document is a standard regulatory filing regarding stock option grants, which is neutral in sentiment.

Positives

• The grant of stock options to a director aligns their interests with those of the shareholders.
• The vesting schedule encourages long-term commitment from the director.

Industry Context

Stock option grants are a common form of compensation for directors and executives in publicly traded companies, aligning their interests with shareholders and incentivizing long-term value creation.

Stakeholder Impact

• The stock option grant could potentially dilute existing shareholders if the options are exercised in the future.

Key Dates